Abstract
The development of de novo psoriasis in patients treated with tumor necrosis factor-alpha antagonists is well recognized. The authors hereby report a case of palmplantar pustular psoriasis in a patient with rheumatoid arthritis treated with etanercept. The condition responded to topical steroids but re-occurred upon treating the patient with certolizumab pegol. This strongly suggests that the development of de novo psoriasis is a class effect.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 40-41 |
| Number of pages | 2 |
| Journal | Journal of Clinical and Aesthetic Dermatology |
| Volume | 5 |
| Issue number | 8 |
| State | Published - Aug 1 2012 |
ASJC Scopus subject areas
- Dermatology
Fingerprint Dive into the research topics of 'A case of palmoplantar pustulosis induced by certolizumab pegol: New anti-TNF-alpha demonstrates the same class effect'. Together they form a unique fingerprint.
Cite this
Shelling, M. L., Vitiello, M., Lanuti, E. L., Miteva, M., Romanelli, P., & Kerdel, F. A. (2012). A case of palmoplantar pustulosis induced by certolizumab pegol: New anti-TNF-alpha demonstrates the same class effect. Journal of Clinical and Aesthetic Dermatology, 5(8), 40-41.